Product
Alpelisib plus Capecitabine
1 clinical trial
2 indications
Indication
Colorectal CancerIndication
PIK3CA Gene MutationClinical trial
A Phase lb/ll, Open Label, Single Arm Study to Assess Efficacy and Safety of Alpelisib and Capecitabine in Patients With PIK3CA Mutant Metastatic Colorectal Cancer Who Failed Two Prior Standard ChemotherapiesStatus: Active (not recruiting), Estimated PCD: 2024-02-28